Myelodysplastic syndrome (MDS) is a group of hematologic disorders characterized by ineffective hematopoiesis, abnormal mesenchymal and hematopoietic stroma, and profound changes in bone marrow cells. The condition results in decreased production of all three types of blood cells (red blood cells, white blood cells, and platelets), leading to anemia, infections, and bleeding. Patients with MDS often have abnormalities in the blood and bone marrow, which may eventually progress to acute myeloid leukemia. MDS is most common in older adults, but can also occur in younger patients.
History of the disease and interesting historical facts
Myelodysplastic syndromes were first described in the 1970s when physicians began pooling clinical observations of patients with similar hematological disorders. Before this, the conditions were mistakenly labeled as acute myeloid leukemia because the similar clinical presentation was misleading. The scientist who made a significant contribution to understanding this pathology was Irving G. Snyder, who in his work emphasized the progressive nature of MDS and the necessary diagnostic criteria. Subsequently, research continued to deepen, identifying more specific mutations and genetic abnormalities associated with myelodysplasia.
Epidemiology
Statistical data show that myelodysplastic syndromes have a complex epidemiological picture. According to the results of large studies, the incidence of MDS is about 4-10 cases per 100,000 population per year, and age indicators vary greatly. The pathology is most often observed in people over 60 years old, with more than 70% of all cases of this syndrome recorded in this age group. Studies show that in recent decades the number of MDS cases has increased, which may be due to increased life expectancy and improved diagnostic technology.
Genetic predisposition to this disease
An important aspect in the development of myelodysplastic syndrome is its genetic predisposition. The most frequently noted genetic abnormalities are mutations in genes such as TP53, ASXL1, DNMT3A and TET2. These genetic changes can lead to disruption of cellular differentiation and proliferation processes. In some cases of the disease, chromosomal aberrations such as deletions of 5q, 7q and trisomy 8 are observed. It is important to note that hereditary syndromes, including sideroblastic anemia, can also predispose to the development of MDS, emphasizing the need for genetic counseling for targeted risk groups.
Risk factors for the development of this disease
There are several risk factors that contribute to the development of myelodysplastic syndrome:
- Smoking status, which increases the likelihood of developing hematological diseases.
- Working with chemicals such as benzene and heavy metals.
- Prior radiation and chemotherapy for other malignancies.
- Chronic diseases such as viral infections (eg, hepatitis, HIV).
- Hereditary factors - the presence of cases of leukemia in the family.
Each of these factors can contribute to the course of the disease and cause mutations in stem cells.
Diagnosis of this disease
Diagnosis of myelodysplastic syndrome involves many elements, ranging from clinical manifestations to laboratory tests:
- Main symptoms: anemia, fatigue, frequent infections, bleeding.
- Laboratory tests: A general blood test reveals abnormalities in the quantity and quality of formed elements, and a bone marrow microscopy is performed to detect dyserythropoiesis.
- Radiological examinations: are used to exclude other pathologies and assess the condition of internal organs.
- Other types of diagnostics: cytogenetic analysis to detect chromosomal changes.
- Differential diagnosis: It is necessary to distinguish MDS from other hematological diseases, such as myeloma, acute leukemia and aplastic anemia.
This comprehensive diagnostics allows us to accurately determine the diagnosis and begin appropriate treatment.
Treatment
Treatment of myelodysplastic syndrome is a complex and multi-stage task that requires an individual approach:
- General treatment: includes supportive therapy, including blood transfusions for severe anemia and the use of agents that promote hematopoiesis stimulation.
- Pharmacological treatment: may include methyltestosterone, antioxidants, and corticosteroids to reduce inflammatory responses.
- Surgical treatment: related to possible bone marrow transplantation for young and suitable patients.
- Other types of treatment: include immunotherapy as well as the use of new experimental drugs such as hypomethylating agents.
The main goal of treatment is to control symptoms, slow the progression of the disease and improve the quality of life of patients.
List of medications used to treat this disease
There are various medications that are used to treat myelodysplastic syndrome:
- Azathioprine
- Dexaemethasone
- Hydroxyurea
- Lenalidomide
- Demethylaminocholine
- 5-azacytidine (atraguline)
- Cyclosporine A
These drugs help manage symptoms and slow the progression of the disease.
Disease monitoring
Monitoring the condition of a patient with myelodysplastic syndrome is important to assess the effectiveness of treatment and identify possible complications:
- Control stages: regular blood tests, cytogenetic studies and bone marrow assessment.
- Forecast: depends on the MDS subtype, the general condition of the patient and the effectiveness of treatment, but in general the prognosis is unstable.
- Complications: may include infections, thrombocytopenic disorders, and the development of acute myeloid leukemia.
This Monitoring allows you to promptly identify changes and respond to them.
Age-related features of the disease
Myelodysplastic syndromes show different clinical manifestations and course depending on the age group:
- Elderly patients: have a greater predisposition to long-term chronic diseases and often a more complex course with a higher probability of progression to acute leukemia.
- Young patients: may have a more favorable prognosis and respond better to treatment, but are also more likely to have a genetic predisposition.
Thus, age influences the appropriate approaches to diagnosis and treatment.
Questions and Answers
- What is myelodysplastic syndrome? MDS is a group of diseases characterized by a disorder of hematopoiesis and the possibility of progression to acute myeloid leukemia.
- What are the main symptoms of myelodysplastic syndrome? The main symptoms include anemia, fatigue, frequent infections and bleeding due to low platelet levels.
- How is myelodysplastic syndrome diagnosed? Diagnosis includes blood tests, bone marrow microscopy, cytogenetic studies and assessment of the patient's general condition.
- What are the treatment options for myelodysplastic syndrome? Treatment may include supportive care, medications, bone marrow transplants, and other methods aimed at symptomatic relief.
- What is the prognosis for patients with myelodysplastic syndrome? Prognosis depends on the MDS subtype, the patient's overall condition and response to treatment; complications can seriously impair outcome.
Myelodysplastic syndrome remains a pressing issue in hematology, requiring a deep understanding of the mechanisms of its development, diagnostic methods and treatment to improve the quality of life of patients.
